Date Ribbon

8:30 am Online Registration & Virtual Coffee Networking

EXPANDING THE CLINICAL UTILITY OF JAK INHIBITORS ACROSS MULTIPLE DISEASES

9:00 am Challenges & Opportunities of JAKi in Conventional & Less Conventional Disease Status

Synopsis

  • IMMD rheumatologic and dermatologic conditions: the benefit-risk and value proposition paradigm
  • How to explore other potential roles of JAKi?

9:20 am JAK Inhibition in COVID19

Synopsis

  • Rationale for inhibition of JAK kinases during COVID19 pathology
  • Discussion of results in animal models of SARS and cytokine storms
  • Review of initial results from pilot clinical trials in COVID19

9:40 am JAK Inhibitors as a Therapeutic Strategy for Inflammatory & Rheumatic Diseases

  • Massimo Gadina Chief, Translational Immunology Section, National Institute of Arthritis & Musculoskeletal & Skin Diseases

Synopsis

  • Reviewing the most recent findings related to JAK inhibitors’ mechanism of action and selectivity
  • Discussing some of the diseases for which inhibition of the JAK-STAT pathway is proving to bea successful therapeutic approach or for which these drugs are actively investigated
  • Outlining the effect of JAK inhibitors on circulating immune cells, in particular NK cells and compare these to the effects on another type I innate lymphoid cells,
    ILC1

DEFINING VIABLE RESEARCH & PRODUCT STRATEGIES TO HIT THE JAK-POT

10:00 am Live Discussion & Question Time

  • Anabela Cardoso Global Brand Development Lead, Immunology, Eli Lilly
  • Joaquin Espinosa Professor, University of Colorado Anschutz Medical Campus
  • Massimo Gadina Chief, Translational Immunology Section, National Institute of Arthritis & Musculoskeletal & Skin Diseases

Synopsis

  • Understanding major unmet clinical needs to identify logical expansion of research efforts and clinical expansion strategies for JAK inhibitors
  • Discussing clinical data requirements and other evidence needed to inform research and product development strategies
  • Collaborating with healthcare professionals and regulatory bodies to understand patient access landscapes and facilitate with strategic planning

10:30 am Virtual Speed Networking

Synopsis

Grab a quick cup of tea or coffee from the comfort of your own kitchen and jump straight into your opportunity to connect with new contacts from active companies in the field and exchange digital business cards. Network and form lasting connections through this exclusive virtual speed networking!

IMPROVING JAK INHIBITOR UTILITY THROUGH RATIONAL TRIAL DESIGN & PATIENT STRATIFICATION

11:00 am Understanding JAK Inhibitor Treatment Strategies for Patients with Myeloproliferative Neoplasms

Synopsis

  • Rationale for JAK inhibition in MPN
  • Success and limitations of JAK inhibitors in MPN
  • Modern JAK inhibitor-based combination therapy approaches

11:20 am Trials & Progress from MOMENTUM Study in Myelofibrosis

Synopsis

  • Optimizing clinical trial design with enhanced biological endpoints
  • Demonstrating improvement in anemia and reducing transfusion dependency in patients
  • Exploring perspectives on optimal powering and how that influences developmental milestones

11:40 am What’s Been Right & Wrong in the Clinical Trial Programs of JAK Inhibitors for Rheumatoid Arthritis (RA) & What can be Improved?

  • Roy Fleischmann Co-Medical Director Metroplex Clinical Research Center, Clinical Professor of Medicine, University of Texas Southwestern Medical Center

Synopsis

  • What has been done correctly in each of the clinical trial programs for JAK inhibitors in RA?
  • What could have been done better in each of the clinical trial programs for JAK inhibitors in RA?
  • Suggestions for better clinical trial design of JAK inhibitors in RA with more meaningful results

12:00 pm Live Discussion & Question Time

  • John Mascarenhas Associate Professor, Mount Sinai School of Medicine
  • Barbara Klencke Chief Development Officer, Sierra Oncology
  • Roy Fleischmann Co-Medical Director Metroplex Clinical Research Center, Clinical Professor of Medicine, University of Texas Southwestern Medical Center

Synopsis

  • What are the clinical cross-learnings for JAK inhibitor application across both blood-related disorders and immune-mediated diseases?
  • How can we refine clinical trial protocols to include clinically meaningful biomarkers with improved predictability of patient response and clinically meaningful endpoints?
  • In what clinical indications do effective combination regimens that include JAK inhibitors play a role and how can these combinations be optimized?

UNDERSTANDING TRIAL DESIGN CONSIDERATIONS FOR NEXT GENERATION SUPERIOR JAK INHIBITOR DEVELOPMENT

12:30 pm Networking Lunch & Roundtable Discussions

One key benefit of a digital conference is that you probably will not be missing hotel conference food! So grab your own lunch and get stuck into the virtual roundtable discussions that enable more intimate and open discussions on some of the hottest topics and key areas of debate. Drive your own learning, crowd-source ideas and get inspired. Immerse yourself in the following discussions:

Roundtable A: JAK Inhibitors in Dermatology Indications (e.g. Atopic Dermatitis)

Kimberly McHale

Kimberly McHale
Director of Non-Clinical Science &
Development Program Leader
Dermavant

Roundtable B: JAK Inhibitors in Down Syndrome

Kelly Sullivan

Kelly Sullivan
Assistant Professor
University of Colorado Anschutz Medical
Campus

OPTIMIZING JAK INHIBITOR CLINICAL OUTCOMES IN DERMATOLOGY

1:30 pm Treatment for Alopecia Areata to Vitiligo: JAK Inhibitors & The Golden Age of Dermatology

  • Brett King Associate Professor of Dermatology, Yale School of Medicine

Synopsis

  • Describe the broad utility of JAK inhibitors across dermatological diseases, including alopecia areata, atopic dermatitis, dermatomyositis, granuloma annulare and sarcoidosis, lichen planus, morphea, psoriasis, and vitiligo
  • Identify challenges of clinical trials in dermatological orphan diseases

1:50 pm Designing Translational Medicine Approaches: Topical Cerdulatinib – Case Studies in Atopic Dermatitis & Vitiligo

  • Kimberly McHale Director of NonClinical Science & Development Program Leader, Dermavant

Synopsis

  • Topical cedulatinib and the beneficial pharmacology of dual targeting of JAK and SYK signaling pathways
  • Translational medicine of topical cerdulatinib: case studies in Atopic Dermatitis and vitiligo

2:10 pm Development of JAK Inhibitors for Chronic Itch

  • Brian Kim Associate Professor & Founder/Chief Scientific Officer, Washington University School of Medicine & Nuogen Pharma

Synopsis

  • Target identification in new tissue
  • Proving mechanisms of action
  • Developing novel route of delivery

2:30 pm Live Discussion & Question Time

  • Brett King Associate Professor of Dermatology, Yale School of Medicine
  • Kimberly McHale Director of NonClinical Science & Development Program Leader, Dermavant
  • Brian Kim Associate Professor & Founder/Chief Scientific Officer, Washington University School of Medicine & Nuogen Pharma

Synopsis

  • What are the clinical cross-learnings for JAK inhibitor application across both blood-related disorders and immune-mediated diseases?
  • How can we refine clinical trial protocols to include clinically meaningful biomarkers with improved predictability of patient response and clinically meaningful endpoints?
  • In what clinical indications do effective combination regimens that include JAK inhibitors play a role and how can these combinations be optimized?

ARE JAK INHIBITORS THE FUTURE OF DERMATOLOGY DRUG DEVELOPMENT?

3:00 pm Final Virtual Speed Networking Opportunity

3:30 pm Afternoon Discussion Session

  • Leandro Santos Associate Director, Clinical Sciences, Incyte
  • Brian Kim Associate Professor & Founder/Chief Scientific Officer, Washington University School of Medicine & Nuogen Pharma
  • Ruben Mesa Director, UT Health San Antonio MD Anderson Cancer Center

Synopsis

  • What are the various forms of administration for JAK inhibitors?
  • How can we balance exposure/safety with clinical response through different routes of administration?
  • Pros and cons of oral, dermal and inhaled delivery on pharmacokinetics, pharmacodynamics and safety profile
  • Formulation challenges and opportunities of different dosage forms of JAK inhibitors

4:10 pm Development of JAK Inhibitor Topical Products: Early Screening & Prototype Optimization”

Synopsis

  • Are you interested in bringing a JAK inhibitor to the dermatology market?
  • Developing the molecule as a topical product may be challenging, learn the Tergus approach!

EMERGING MODALITIES OF JAK INHIBITORS FOR OPTIMAL ROUTE OF DELIVERY

4:30 pm End of Summit & Virtual Happy Hour Begins

Synopsis

The time of day we’ve all been waiting for! Grab a beverage of your choice from your home bar and use this final networking opportunity to follow up on connections made earlier in the day, ask that burning question to a speaker whose talk got you thinking and forge relations that could lead to your next collaboration.

5:30 pm End of Virtual Happy Hour

Bonus Content

Dual JAK/ROCK Inhibitors: Moving JAK Inhibition to the New Therapeutic Avenues Where Anti-Inflammation & Anti-Fibrotic Activity is Needed

Synopsis

  • Tools, technologies and models used to achieve preclinical development and mechanistic understanding of the candidate
  • Medicinal chemistry approaches used to optimize drug selectivity
  • How preclinical selectivity will translate into clinical control of disease as the candidate is prepared for clinical trials

Filgotinib: Maturing the JAK1 Profile

Synopsis

  • Discussing how JAK1 inhibitors are promising the next generation of anti-inflammatory drugs
  • Growing understanding of JAK1 pharmacology leads to better drugs
  • Exploring how oral drugs can replace many injectables in the inflammatory space

Tofacitinib Modulates Cardiometabolic & Immunologic Disease Markers Associated with Premature Atherosclerosis in SLE

  • Sarfaraz Hasni Director Lupus Clinical Research, National Institute of Arthritis, Musculoskeletal, and Skin Diseases (NIAMS) of the National Institutes of Health (NIH)

Synopsis

  • JAK inhibitors can mitigate the aberrant activation of innate immune pathways in SLE
  • Tofacitinib is not associated with severe adverse events when used in mild-moderate SLE
  • Tofacitinib increases the number and size of high density lipoprotein particles and vascular endothelial dysfunction, associated with premature atherosclerosis in SLE